Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3433685 | 0.88 | TDP1 (0.53) | CTSVCTSLALDH1A1KDM4ELMNA | |
| SCHEMBL6007713 | 0.82 | TDP1 (0.52) | ALDH1A1GAASMN1; SMN2PARP1KMT2A | |
| SCHEMBL7491879 | 0.81 | PARP1 (0.62) | CTSVCTSLALDH1A1KDM4ELMNA | |
| SCHEMBL11568200 | 0.81 | GRIN2D (0.56) | CTSVCTSLALDH1A1KDM4ELMNA | |
| SCHEMBL25800756 | 0.79 | KMT2A (0.55) | CTSVCTSLALDH1A1GAAPARP1 | |
| SCHEMBL1799350 | 0.77 | TYMS (0.47) | ALDH1A1KDM4ELMNAHPGDPARP1 | |
| SCHEMBL29478497 | 0.77 | MAPT (0.57) | ALDH1A1KDM4EGLAHPGDSMN1; SMN2 | |
| SCHEMBL28907048 | 0.77 | MAPT (0.57) | ALDH1A1KDM4EGLAHPGDSMN1; SMN2 | |
| SCHEMBL10345038 | 0.77 | ALDH1A1 (0.74) | CTSVCTSLALDH1A1KDM4ELMNA | |
| SCHEMBL7220724 | 0.75 | SIRT2 (0.46) | CTSVCTSLALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100456398-C | Electrolyte for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORP (JP) | 2009-01-28 | — | — | CN | claimed |
| CN-1529892-A | Electrolyte for driving electrolytic capacitor and electrolytic capacitor | 如碧空株式会社 | 2004-09-15 | — | — | CN | claimed |
| CN-100456398-C | Electrolyte for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORP (JP) | 2009-01-28 | — | — | CN | disclosed |
| WO-2008016661-A2 | MORPHOLINO COMPOUNDS FOR TREATING INFLAMMATORY AND DEMYELINATING DISEASES AND CANCERS | XANTHUS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| EP-0977738-B1 | CYCLIN DEPENDENT KINASE (CDK)4 INHIBITORS AND THEIR USE FOR TREATING CANCER | US HEALTH (US) | 2005-11-16 | — | — | EP | disclosed |
| CN-1529892-A | Electrolyte for driving electrolytic capacitor and electrolytic capacitor | 如碧空株式会社 | 2004-09-15 | — | — | CN | disclosed |
| US-20040006074-A1 | Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer | THE GOVERNMENT OF THE UNITED STATES OF AMERICA | 2004-01-08 | — | — | US | disclosed |
| US-6630464-B1 | Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-10-07 | — | — | US | disclosed |
| EP-0977738-A2 | CYCLIN DEPENDENT KINASE (CDK)4 INHIBITORS AND THEIR USE FOR TREATING CANCER | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998049146-A2 | CYCLIN DEPENDENT KINASE (CDK)4 INHIBITORS AND THEIR USE FOR TREATING CANCER | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH (US) | 1998-11-05 | — | — | WO | disclosed |
| EP-0111205-B1 | ACRIDANONE DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1987-04-01 | — | — | EP | disclosed |
| US-4544659-A | PARASITICIDES | HOFFMAN-LA ROCHE INC. (US) | 1985-10-01 | — | — | US | disclosed |
| EP-0111205-A1 | Acridanone derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006074-A1 | Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer | CDK4, CCNI, CDK2 | CTSV 2995/4885CTSL 2385/4885ALDH1A1 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.